Proton pump inhibitors
ATC code: A02BC02 (Pantoprazole)
Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells. Same mechanism as omeprazole. A distinctive feature of pantoprazole is its weaker CYP2C19 inhibition. This underpinned the 2009 caution about omeprazole–clopidogrel interaction, but the clinical relevance has been refuted by the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies: no difference in cardiovascular outcomes between DAPT patients on different PPIs. Pantoprazole remains a reasonable choice in clopidogrel-treated patients, but this is no longer a critical advantage.
First line
First-line GERD therapy. PPIs are the most effective agents for acid suppression. Pantoprazole 40 mg once daily 30 minutes before breakfast. Course 4–8 weeks, then attempt dose reduction or on-demand dosing.
First line
First-line prophylaxis of gastropathy in patients on long-term NSAIDs with risk factors – age over 65, ulcer history, concomitant anticoagulants or corticosteroids. Pantoprazole 20 mg once daily for the duration of NSAID therapy.
First line
First-line for peptic ulcer disease. Duodenal ulcer course is 4 weeks, gastric ulcer 8 weeks. In H. pylori eradication, any PPI at double dose twice daily. Pantoprazole is preferred in patients on clopidogrel after coronary stenting.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Pantoprazole is a proton pump inhibitor (PPI). It is prescribed for GERD, peptic ulcer, Helicobacter pylori eradication, and gastroprotection with NSAID use in patients at high GI bleeding risk – age over 65, ulcer history, concomitant anticoagulants or corticosteroids ( 2022, 2020). In low-GI-bleeding-risk patients on short-term NSAIDs, routine PPI gastroprotection is not justified: long-term PPI use is linked to specific risks – vitamin B12 and magnesium deficiency, elevated risk of intestinal infections (Clostridioides difficile), pneumonia, hip and vertebral fractures (via impaired calcium absorption), and chronic kidney disease. If pantoprazole was prescribed for long-term use without confirmed high GI risk, consider seeking a second opinion.
3 pairs found. Sorted from critical to minor.
Mechanism
Proton pump inhibitors block the renal BCRP transporter, reducing methotrexate clearance. At high oncologic doses: risk of severe delayed toxicity.
Symptoms
Mouth ulcers (mucositis), nausea, diarrhoea, hair loss. Blood counts fall: leukocytes, platelets, erythrocytes. Severe cases: fatal pancytopenia, nephrotoxicity.
Management
At oncologic methotrexate doses, stop pantoprazole 5 days before and resume 5 days after dosing. Alternative: famotidine (H2-blocker, no BCRP effect). At low rheumatologic doses, pantoprazole is acceptable.
Mechanism
Pantoprazole is the most CYP-neutral PPI. No clinically significant interaction with statins.
Symptoms
No changes.
Management
The combination is acceptable without dose change. Pantoprazole is the preferred PPI in patients on statins and other CYP3A4-dependent drugs.
Mechanism
Pantoprazole reduces gastric acidity and B12 release from food. With long-term therapy, B12 deficiency risk is reported, similar to other PPIs.
Symptoms
Fatigue, pallor, paraesthesias in hands and feet, gait instability, memory decline. Develops over 2–4 years of unrecognised therapy.
Management
On long-term pantoprazole (over 2 years), check B12 yearly. Cyanocobalamin can be given regardless of acidity (passive diffusion absorption at high doses). For sustained acid suppression, consider dose reduction or periodic breaks.
Sources
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.
Compatible. Hale L2. Transfers into milk in small amounts (RID about 1%); infant gastric acid inactivates the molecule before meaningful systemic absorption. AEG and AAP consider it compatible; a nursing mother on reflux or ulcer therapy can continue breastfeeding. The infant may show mild functional gut symptoms (flatulence, stool changes) that usually resolve on their own.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Pantoprazole is evaluated for the following indications with varying evidence strength: NSAID gastropathy prophylaxis (evidence tier A), Gastroesophageal reflux disease (evidence tier A), Peptic ulcer disease (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Pantoprazole (≥ 1 in 100): Headache, Diarrhea, Nausea, Flatulence, Abdominal pain. See the Safety section for uncommon and serious reactions.
FDA category B. FDA category B. Safety data in pregnancy are limited, but animal studies have shown no teratogenic effect. Used when clearly indicated.
Compatible. Hale L2. Transfers into milk in small amounts (RID about 1%); infant gastric acid inactivates the molecule before meaningful systemic absorption. AEG and AAP consider it compatible; a nursing mother on reflux or ulcer therapy can continue breastfeeding. The infant may show mild functional gut symptoms (flatulence, stool changes) that usually resolve on their own.
Pantoprazole is contraindicated in: Hypersensitivity to PPIs. Full list in the Safety section.